Literature DB >> 30811149

Pustular DRESS Syndrome Secondary to Hydroxychloroquine With EBV Reactivation

Raghavendra L. Girijala, Imaad Siddiqi, Young Kwak, David Wright, Dhruti B. Patel, Leonard H. Goldberg.   

Abstract

Background: Drug reaction with eosinophilia and systemic symptoms (DRESS syndrome) or drug-induced hypersensitivity (DIHS) is a rare and feared complication of frequently used medications such as anticonvulsants, sulfonamides, and allopurinol. To date, no reports of hydroxychloroquine-induced pustular DRESS syndrome have been associated with Epstein-Barr virus (EBV) reactivation nor imitated other cutaneous adverse drug reactions as in our patient. Observation: A 56-year-old female presented with a diffuse cutaneous eruption involving the face, trunk, extremities, and palms approximately two weeks after the initiation of hydroxychloroquine therapy for a suspected Sjögren's-like process with inflammatory cervical lymphadenopathy. Skin examination demonstrated diffuse erythematous and edematous papules and pustules on her dorsal and volar hands and fingers, arms, legs, chest, abdomen, back, scalp, and face. In many areas, lesions coalesced into plaques with overlying pustules, scale, and crust. Additional notable exam findings included centralized facial edema, edema of the hands, and cervical lymphadenopathy. Laboratory workup revealed leukocytosis, peripheral eosinophilia, elevated transaminases, and a negative autoimmune workup; however, serology demonstrated EBV reactivation. Histologic assessment displayed a spongiotic dermatitis with eosinophils, superficial perivascular dermatitis, as well as corneal, subcorneal, and intraepidermal neutrophilic microabscesses, mimicking acute generalized exanthematous pustulosis or pustular psoriasis, even though clinical evaluation suggested DRESS syndrome.
Conclusion: To our knowledge, this is the first reported case of hydroxychloroquine-induced pustular DRESS syndrome in the context of EBV reactivation. Given hydroxychloroquine’s immunomodulatory function and association with other cutaneous manifestations, our patient represents a significant diagnostic challenge. Therefore, this case highlights the importance of knowledge regarding overlapping features, histologically and clinically, among acute generalized exanthematous pustulosis, pustular psoriasis, and DRESS syndrome. J Drugs Dermatol. 2019;18(2):207-209.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30811149

Source DB:  PubMed          Journal:  J Drugs Dermatol        ISSN: 1545-9616            Impact factor:   2.114


  9 in total

Review 1.  Safety considerations with chloroquine, hydroxychloroquine and azithromycin in the management of SARS-CoV-2 infection.

Authors:  David N Juurlink
Journal:  CMAJ       Date:  2020-04-08       Impact factor: 8.262

Review 2.  Safety of Short-Term Treatments with Oral Chloroquine and Hydroxychloroquine in Patients with and without COVID-19: A Systematic Review.

Authors:  Sergio Marin; Alba Martin Val; Maite Bosch Peligero; Cristina Rodríguez-Bernuz; Ariadna Pérez-Ricart; Laia Vilaró Jaques; Roger Paredes; Josep Roca; Carles Quiñones
Journal:  Pharmaceuticals (Basel)       Date:  2022-05-21

Review 3.  [Adverse reactions of drugs specifically used for treatment of SARS-CoV-2 infection].

Authors:  Valeria Herrera-Lasso Regás; María Teresa Dordal Culla; Ramón Lleonart Bellfill
Journal:  Med Clin (Barc)       Date:  2020-07-09       Impact factor: 1.725

4.  Drug reaction with eosinophilia and systemic symptoms syndrome to hydroxychloroquine, an old drug in the spotlight in the COVID-19 era.

Authors:  Mauro Grandolfo; Paolo Romita; Domenico Bonamonte; Gerardo Cazzato; Katharina Hansel; Luca Stingeni; Claudio Conforti; Roberta Giuffrida; Caterina Foti
Journal:  Dermatol Ther       Date:  2020-05-22       Impact factor: 2.851

5.  Hydroxychloroquine-induced erythroderma: A rare adverse effect of a commonly used drug.

Authors:  Ananta Khurana; Anusha Katare; Aastha Agarwal; Priyadharshini Kathirvel; Arvind Ahuja
Journal:  Dermatol Ther       Date:  2020-09-08       Impact factor: 3.858

Review 6.  Review of adverse cutaneous reactions of pharmacologic interventions for COVID-19: A guide for the dermatologist.

Authors:  Antonio Martinez-Lopez; Carlos Cuenca-Barrales; Trinidad Montero-Vilchez; Alejandro Molina-Leyva; Salvador Arias-Santiago
Journal:  J Am Acad Dermatol       Date:  2020-08-07       Impact factor: 11.527

Review 7.  Generalized pustular figurate erythema: A newly delineated severe cutaneous drug reaction linked with hydroxychloroquine.

Authors:  Robert A Schwartz; Camila K Janniger
Journal:  Dermatol Ther       Date:  2020-04-16       Impact factor: 3.858

8.  Drug reaction with eosinophilia and systemic symptoms syndrome in a patient with COVID-19.

Authors:  A Herman; M Matthews; M Mairlot; L Nobile; L Fameree; L-M Jacquet; M Baeck
Journal:  J Eur Acad Dermatol Venereol       Date:  2020-07-31       Impact factor: 6.166

9.  Diagnosis and management of the drug hypersensitivity reactions in Coronavirus disease 19: An EAACI Position Paper.

Authors:  Aslı Gelincik; Knut Brockow; Gülfem E Çelik; Inmaculada Doña; Cristobalina Mayorga; Antonino Romano; Özge Soyer; Marina Atanaskovic-Markovic; Annick Barbaud; Maria Jose Torres
Journal:  Allergy       Date:  2020-07-01       Impact factor: 14.710

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.